Spineart secured a €30MM (~US $33MM) investment. Proceeds will support sales, geographical expansion in markets such as the U.S. and Europe and product development.
Funds were provided by Gimv, an investment company, and Health and Care Fund.
Spineart has secured numerous FDA 510(k) clearances in the U.S. since 2008, and was recently granted CE Mark Approval for its JULIET®Ti lumbar interbody systems featuring TI-LIFE, a micro-porous scaffold designed to mimic trabecular bone.
Spineart secured a €30MM (~US $33MM) investment. Proceeds will support sales, geographical expansion in markets such as the U.S. and Europe and product development.
Funds were provided by Gimv, an investment company, and Health and Care Fund.
Spineart has secured numerous FDA 510(k) clearances in the U.S. since 2008, and was recently...
Spineart secured a €30MM (~US $33MM) investment. Proceeds will support sales, geographical expansion in markets such as the U.S. and Europe and product development.
Funds were provided by Gimv, an investment company, and Health and Care Fund.
Spineart has secured numerous FDA 510(k) clearances in the U.S. since 2008, and was recently granted CE Mark Approval for its JULIET®Ti lumbar interbody systems featuring TI-LIFE, a micro-porous scaffold designed to mimic trabecular bone.
Copy to clipboard 
